cbdMD Generates $19.1 Million in Year Over Year Reduction in Net Loss Improvement

Finishes the year with a stronger cash position.

Charlotte, North Carolina–(Newsfile Corp. – December 18, 2024) – cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation’s leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for the full fiscal year ended September 30, 2024.

For Fiscal 2024, we continued to make strong progress on our turnaround. The Company incurred a loss from operations of only $3.3 million, or a $19.1 million year-over-year improvement from the $22.9 million loss in the prior year. This is the second consecutive year of strong financial and operational improvements, accomplished despite revenue challenges.

“We made tremendous strides in strengthening our operational foundation and moving closer to our goal of profitability,” said Ronan Kennedy, CEO and CFO of cbdMD. “While the fourth quarter presented temporary revenue headwinds, for the fiscal year we successfully executed key initiatives to lower our operating costs, including the elimination and settlement of our headquarter (HQ) lease obligations, and strengthening our cash position through disciplined working capital management and outside investment. With revenues rebounding, we project Q1 fiscal 2025 revenues to approach $5 million, putting us back on track to accelerate our growth trajectory.”

Kennedy continued: “We are laser-focused on delivering positive non-GAAP EBITDA in fiscal 2025. Our operational advancements in 2024 have provided a more stable and scalable platform, and we’ve entered 2025 with a strong cash position, improved marketing metrics, and exciting new products driving consumer engagement. Notably, the launch of our Herbal Oasis functional beverage in November has been met with enthusiastic early feedback.”

As part of its growth strategy, the company remains committed to addressing its equity capital structure to unlock additional shareholder value and ensure compliance with NYSE American standards.

Kennedy added: “2024 was a year of transformation for cbdMD. We’ve demonstrated our ability to execute against goals and overcome challenges, all while keeping our focus on creating long-term value for our shareholders. We are confident in our direction, and our entire team is energized to continue driving growth, innovation, and operational excellence in 2025.”

cbdMD enters fiscal 2025 as a leaner, more agile company, ready to build on its turnaround momentum. With a portfolio of trusted brands, a disciplined approach to financial management, and a commitment to innovation, cbdMD is well-positioned to lead in the evolving CBD and wellness markets.

Highlights for Fiscal 2024 and Notable Business Updates

• The Company launched its brand of functional mushrooms, ATRx Labs, initially through Amazon US and subsequently launched systemwide in GNC during the spring.

• cbdMD expanded its successful line of D-9 products entering the fast-growing beverage category with its Mixers and Herbal Oasis Social Tonic.

• The Company successfully negotiated an exit to its HQ lease in August, saving approximately $1.2 million a year in fixed costs.

• cbdMD secured $1.25 million in net financing through $1.5 million convertible Notes during the second fiscal quarter to bolster its working capital.

• The Company received notice from the NYSE American that is has accepted the Company’s plan of compliance. During the plan period, the Company will be subject to quarterly review to determine if it is making progress consistent with the plan. If the Company does not regain compliance with the NYSE American listing standards by December 5, 2025, or if the Company does not make sufficient progress consistent with its plan, then the NYSE American may initiate delisting proceedings. NYSE American requires that cbdMD’s net book value of equity must be at least $4 million. At fiscal year end, it totaled approximately $2.0 million, which was negatively impacted by the $4.7 million of Series A Preferred accrued dividends.

• The results from cbdMD’s double blind placebo controlled clinical trial were published in the Journal of the International Society of Sports Nutrition in June 2024, highlighting the demonstrated reduction of pain, reduced inflammation and improved mood using a 100mg / day regimen of cbdmd’s broad spectrum

• The results from cbdMD’s double blind placebo controlled clinical study in dogs performed in conjunction with Colorado State university’s veterinary program were published in Frontiers in Veterinary Science in September 2024. The study emphasized cbdMD’s broad spectrum product improved mobility, gait and quality of life in dogs with osteoarthritis.

Financial Highlights from our Fiscal Year 2024:

• Net sales totaled $19.5 million in fiscal 2024 or a decrease of 19.1% compared to $24.1 million in fiscal 2023.

• Our gross profit for the year was flat at 62% in fiscal 2024 compared to 62% in fiscal 2023.

• Our loss from operations was $3.3 million in fiscal 2024 as compared to a loss of $22.4 million in fiscal 2023.

• Our non-GAAP adjusted EBITDA loss from operations in fiscal 2024 was approximately $1.5 compared to our non-GAAP adjusted EBITDA from operations in fiscal 2023 of approximately $5.5. million, despite the decline in revenue. Our non-GAAP adjusted EBITDA loss for the second half of 2024 was reduced to only $0.2 million from $1.2 million in the prior year comparative period.

• Net loss attributable to common shareholders for fiscal 2024 was approximately $7.7 million or $1.79 per share as compared to a net loss for fiscal 2023 of approximately $26.9 million, or $13.30 per share. The improvement in fiscal 2024 was principally attributable to ongoing management’s efforts on improving profitability, as well as the $13.2 million intangible impairment during 2023.

• At September 30, 2024, we had working capital of approximately $1.1 million and cash on hand of approximately $2.4 million (which includes $4.7 million of accrued Series A dividend payments) as compared to working capital of approximately $3.4 million and cash on hand of approximately $1.8 million (which includes $0.67 million of accrued Series A dividend payments) at September 30, 2023.

• We reported direct to consumer (DTC) net sales of $15.7 million or 80.4% of total net sales in fiscal 2024, a decrease of $3.9 million, or 19.9% from fiscal 2023.

• As of the filing date of our annual report, the majority of our Notes have been converted and the balance of the Notes totaled approximately $0.36 million. When factoring in our cash balance of $2.4 million at the end of September 30, 2024 and ongoing cash consumption rate, management believe the Company has a strong liquidity position going into calendar 2025.

Pursuant to the disclosure requirements of the NYSE American Company Guide Section 610(b), cbdMD is reporting that its audited consolidated financial statements for the fiscal year ended September 30, 2024, included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 18, 2024, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to cbdMD’s ability to continue as a going concern. This announcement does not represent any change or amendment to cbdMD’s financial statements or to its Annual Report on Form 10-K for the fiscal year ended September 30, 2024.

We will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, December 18, 2024, to discuss our September 30, 2024, fourth quarter and full fiscal year financial results and business progress.

CONFERENCE CALL DETAILS

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free¹ CBD products, including NSF Certified for Sport® products, as well as our new Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD sleep aids and CBD drink mixes and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free¹ CBD oil and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, or ATRxlabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD’s products.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, continued cost reductions, potential need for additional working capital, regaining compliance with NYSE American continued listing standards, continued listing on the NYSE American, future profitability, development and sales of new products, and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as filed with the Securities and Exchange Commission (the “SEC”) on December 17, 2024, and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

¹ THC-free is defined as below the level of detection using validated scientific analytical methods.

Non-GAAP Financial Measures

This press release includes a financial measure that excludes the impact of certain items and therefore has not been calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). cbdMD, Inc. has included adjusted loss from operations because management uses this measure to assess operating performance in order to highlight trends in our business that may not otherwise be apparent when relying on financial measures calculated in accordance with GAAP. The adjusted operating loss has not been prepared in accordance with GAAP. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, net loss from operations as an indicator of our operating performance. Further, this non-GAAP financial measure, as presented by cbdMD, Inc., may not be comparable to similarly titled measures reported by other companies. cbdMD, Inc. has attached to this press release a reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure.

(1) Represents non-cash expense related to options, warrants, restricted stock expenses that have been amortized during the period.
(2) Represents an operating expense related to inventory loss related to regulatory changes impacting labels and packaging and obsolete/expired inventory.
(3) Represents non-cash impairment of the cbdMD, DCO and Technology Relief from Royalty trademarks of $13.21 million during the fourth quarter of fiscal 2023, non-cash impairment of the cbdMD trademark of $4.28 million during the first quarter of fiscal year 2022 and $56.67 million of goodwill impairment during the fiscal year ended 2022
(4) Represents non-cash expense incurred as a credit provided to GNC to replace expired product.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234173